InterShunt Technologies

InterShunt Technologies, Inc.InterShunt Technologies, Inc. was founded in 2015 and is headquartered in St. Louis, US. The company develops a proprietary transcatheter system designed to create a left-to-right atrial shunt by safely excising tissue from the interatrial septum. The company has completed two deals since its inception.InterShunt Technologies, Inc. specializes in the development of a proprietary transcatheter system designed to create a left-to-right atrial shunt by safely excising tissue from the interatrial septum. This innovative device aims to alleviate elevated left atrial pressure, addressing the symptoms faced by heart failure patients. The mechanical system requires no implants or energy to operate, differentiating it from other interatrial shunting devices. The primary end users of this technology are cardiac patients suffering from heart failure, particularly those with difficulty breathing due to increased heart pressure.As the InterShunt Percutaneous Atrial Shunt Catheter System is still in development and not commercially available, specific revenue data for InterShunt Technologies, Inc. is not disclosed. The company's revenue model will likely revolve around the eventual sale of its proprietary medical device to healthcare providers, which may involve direct-to-consumer transactions or partnerships with hospitals and clinics. Upon market entry, pricing structures may be influenced by production costs, healthcare reimbursement rates, and competitive analysis within the medical device sector.InterShunt Technologies, Inc. is focused on advancing the development of its InterShunt Percutaneous Atrial Shunt Catheter System (PAS-C) with plans to launch the device once regulatory approvals are obtained. The company aims to expand into new markets, particularly targeting healthcare facilities across the US and potentially internationally.

1. Series A

   Dec 3, 2021

   Amount

   $0.9M

   Investors

   Locked